The history of cancer chemotherapy is as old as cancer itself. With the increase in the complexities of cancer and the development of resistance towards existing anticancer agents, increased attention is now being paid to the advancement of chemotherapy. Some chemotherapeutic agents were discovered by accident or trial-and-error methods while others were found to be useful for neoplasia when they were being evaluated for some other purpose. Broadly, these agents have been classified as alkylating agents, antimetabolites, platinum compounds, antitumor antibiotics and natural products. Hormones and compounds interfering with hormone metabolism are widely used in cancer treatment, besides monoclonal antibodies and small molecules targeting angiogenesis. In this review an attempt is made to discuss the major breakthroughs that have shaped the course of cancer chemotherapy, helping to decrease the mortality as well as lessen the suffering of patients.
SeyfriedTNSheltonLMCancer as a metabolic disease. Nutr Metab (Lond)2010777
2.
NowellPCTumor progression: a brief historical perspective. Semin Cancer Biol2002124261–266
3.
GibbsWWUntangling the roots of cancer. Sci Am2003289156–65
4.
AnandPKunnumakkaraABSundaramCCancer is a preventable disease that requires major lifestyle changes. Pharm Res20082592097–2116
5.
WrightJCCancer chemotherapy: past, present, and future—Part I. J Natl Med Assoc1984768773–784
6.
Cancer Control: Knowledge into action: WHO guide for effective programmes. Policy and advocacyModule 6. Geneva World Health Organization 2008.
7.
World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, FranceInternational Agency for Research on Cancer 2013.
8.
DeVitaVTJrYoungRCCanellosGPCombination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer197535198–110
9.
DeVitaVTJrChuEA history of cancer chemotherapy. Cancer Res200868218643–8653
10.
Understanding chemotherapy; a guide for people with cancer, their families and friends. Cancer Council Australia, June 2012.
11.
HassanMSAnsariJSpoonerDHussainSAChemotherapy for breast cancer (Review). Oncol Rep20102451121–1131
12.
MatthiasJThe chemotherapy of malignant disease – practical and experimental considerations. Postgrad Med J196541475268–276
13.
ChidambaramMManavalanRKathiresanKNanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci201114167–77
14.
HellerJRCancer chemotherapy, history and present status. Bull N Y Acad Med1962385348–363
15.
SneaderWDrug discovery. A history. Chichester, UKJohn Wiley and Sons, Ltd 2005.
16.
GilmanAThe initial clinical trial of nitrogen mustard. Am J Surg19631055574–578
17.
ConnorsTMechanism of action of 2-chloroethylamine derivatives, sulfur mustards, epoxides, and aziridines. In: Sartorelli AC, Johns DG, eds. Antineoplastic and immunosuppressive agentsBerlin, HeidelbergSpringer-Verlag 1975:18-34.
18.
American Cancer Society. The history of cancer. American Cancer Society 2012.
19.
SiddikZHMechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum based drugs. In: Alison MR. The cancer handbook1st editionChichester, UKJohn Wiley & Sons, Ltd 2002.
20.
SmithKJHurstCGMoellerRBSkeltonHGSidellFRSulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J Am Acad Dermatol1995325 Pt 1765–776
21.
World Health Organization Technical Report Series. Chemotherapy of cancerGenevaWHO 1962.
22.
BergelFStockJACyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines. J Chem Soc19542409–2417
23.
LarionovLFShkodinskajaENTroosheikinaVIKhokhlovASVasinaOSNovikovaMAStudies on the anti-tumour activity of p-di-(2-chloroethyl) aminophenylalanine (sarcolysine). Lancet19552696882169–171
24.
AlexanianRHautAKhanAUTreatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA196920891680–1685
25.
AkhdarHLegendreCAninatCMorelFAnticancer drug metabolism: chemotherapy resistance and new therapeutic approaches. In: Paxton J, ed. Topics on drug metabolismRijeka, CroatiaInTech 2012:137-171.
26.
TassoMJBoddyAVPriceLWyllieRAPearsonADIdleJRPharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol1992303207–211
27.
Arsenic and arsenic compounds. IARC Monographs 100C. Lyon, FranceInternational Agency for Research on Cancer 2012.
28.
FarberSDiamondLKMercerRDSylvesterRFJrWolffJATemporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med194823823787–793
29.
KayeSBNew antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer1998783 Suppl 31–7
30.
LiJJLaughing gas, viagra, and lipitor: the human stories behind the drugs we use. Oxford, New YorkOxford University Press 2006:8-21.
31.
WeissAJJacksonLGCarabasiRAn evaluation of 5-fluorouracil in malignant disease. Ann Intern Med1961555731–741
32.
CameronDAGabraHLeonard RCF. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer1994701120–124
33.
ZoliWUliviPTeseiAAddition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res200575R681–R689
34.
LongleyDBHarkinDPJohnstonPG5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer200335330–338
35.
AnsfieldFJRamirezGMackmanSBryanGTCurreriARA ten-year study of 5-flurouracil in disseminated breast cancer with clinical results and survival times. Cancer Res19692951062–1066
36.
BunnellCAWinerEPOral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park)19981210 Suppl 739–43
37.
ButtooASElvesMWIsraëlsMCGRoathOSThe demonstration of the site of action of the antimetabolite drug 6-azauridine by the use of leucocyte cultures. Br Pharmacol Chemother196423190–92
38.
Hargrave-ThomasEYuBReynissonJSerendipity in anticancer drug discovery. World J Clin Oncol2012311–6
39.
MonneretCPlatinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr2011696286–295
40.
KubinyiHChance favors the prepared mind—from serendipity to rational drug design. J Recept Signal Transduct Res1999191-415–39
41.
ComroeJHJrPay dirt: the story of streptomycin. Part I. From Waksman to Waksman. Am Rev Respir Dis19781174773–781
42.
FieldJBThe carcinolytic effect of actinomycin C; a report of clinical studies. Calif Med1957865305–308
43.
FarberSD'AngioGEvansAMitusAClinical studies on actinomycin D with special reference to Wilms’ tumor in children. Ann N Y Acad Sci1960892421–425
44.
WatneALMooreDGorgunBSolid tumor chemotherapy with mitomycin C. Arch Surg1967952175–178
LomovskayaNOttenSLDoi-KatayamaYDoxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene. J Bacteriol19991811305–318
54.
BonadonnaGMonfardiniSDe LenaMFossati-BellaniFClinical evaluation of adriamycin, a new antitumour antibiotic. BMJ196935669503–506
55.
MinottiGMennaPSalvatorelliECairoGGianniLAnthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev2004562185–229
56.
BorchmannPHübelKSchnellREngertAIdarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther199735280–83
57.
JensenPBSørensenBSSehestedMDifferent modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol199345102025–2035
58.
ShenBLiuWNonakaKEnediyne natural products: biosynthesis and prospect towards engineering novel antitumor agents. Curr Med Chem200310212317–2325
59.
San PedroJMBeermanTAGreenbergMMDNA damage by C1027 involves hydrogen atom abstraction and addition to nucleobases. Bioorg Med Chem201220154744–4750
60.
ZhenYSMingXYYuBOtaniTSaitoHYamadaYA new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo)19894281294–1298
61.
ImbertTFDiscovery of podophyllotoxins. Biochimie1998803207–222
62.
MansDRAda RochaABSchwartsmannGAnti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist200053185–198
63.
PrakashOKumarAKumarPAjeetAAnticancer potential of plants and natural products: a review. American Journal of Pharmacological Sciences201316104–115
64.
FarnsworthNFThe role of ethnopharmacology in drug development. Ciba Found Symp199418542–59
65.
GordalizaMGarcíaPAdel CorralJMCastroMAGómez-ZuritaMAPodophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon2004444441–459
YouYPodophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des200511131695–1717
68.
ClarkPISlevinMLThe clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet1987124223–252
69.
HandeKREtoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer199834101514–1521
70.
TiongSHLooiCYHazniHAntidiabetic and antioxidant properties of alkaloids from Catharanthus roseus (L.) G. Don. Molecules20131889770–9784
71.
CraggGMNewmanDJPlants as a source of anti-cancer agents. J Ethnopharmacol20051001-272–79
72.
JohnsonISArmstrongJGGormanMBurnettJPJrThe vinca alkaloids: a new class of oncolytic agents. Cancer Res1963238 Part 11390–1427
73.
van Der HeijdenRJacobsDISnoeijerWHallardDVerpoorteRThe Catharanthus alkaloids: pharmacognosy and biotechnology. Curr Med Chem2004115607–628
74.
MohammadgholiARabbani-ChadeganiAFallahSMechanism of the interaction of plant alkaloid vincristine with DNA and chromatin: spectroscopic study. DNA Cell Biol2013325228–235
75.
WilsonLCreswellKMChinDThe mechanism of action of vinblastine. Binding of [acetyl-3H]vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet microtubules. Biochemistry197514265586–5592
76.
RowinskyEKThe development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med1997481353–374
77.
WallMEWaniMCHistory and future prospects of camptothecin and taxol. In: Cordell GA, ed. The Alkaloids. Chemistry and biologySan DiegoAcademic Press 1998;50:509-536.
78.
GoodmanJWalshVThe story of taxol: nature and politics in the pursuit of an anti-cancer drug. CambridgeCambridge University Press 2001.
79.
RowinskyEKOnettoNCanettaRMArbuckSGTaxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol1992196646–662
80.
HorwitzSBMechanism of action of taxol. Trends Pharmacol Sci1992134134–136
81.
MekhailTMMarkmanMPaclitaxel in cancer therapy. Expert Opin Pharmacother200236755–766
82.
BisseryMCNohynekGSanderinkGJLavelleFDocetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs199563339–355363–368
83.
WallMEWaniMCCamptothecin and taxol: discovery to clinic—thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res1995554753–760
84.
WallMEWaniMCookCPalmerKHMcPhailASimGPlant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1, 2. J Am Chem Soc196688163888–3890
85.
McCabeFLJohnsonRKComparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest1994123308–313
86.
BurrisHAIIIHanauskeARJohnsonRKActivity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst199284231816–1820
87.
FriedmanHSHoughtonPJScholdSCKeirSBignerDDActivity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol1994342171–174
KawatoYAonumaMHirotaYKugaHSatoKIntracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res199151164187–4191
90.
VerschraegenCFLevyTKudelkaAPPhase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol1997152625–631
91.
Food and Drug Administration. NDA 20-571/S-008. Rockville MDFood and Drug Administration 1998.
92.
MunroMHBluntJWDumdeiEJThe discovery and development of marine compounds with pharmaceutical potential. J Biotechnol1999701-315–25
93.
BergmannWFeeneyRJContributions to the study of marine products. XXXII. The nucleosides of sponges. I.1. J Org Chem1951166981–987
94.
MolinskiTFDalisayDSLievensSLSaludesJPDrug development from marine natural products. Nat Rev Drug Discov20098169–85
95.
MartinsAVieiraHGasparHSantosSMarketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar Drugs20141221066–1101
de ClaroRAMcGinnKKwitkowskiVU.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res201218215845–5849
98.
WrightJCCancer chemotherapy: past, present, and future—Part II. J Natl Med Assoc1984769865–876
99.
ColeMPJonesCTAToddIDHA new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer1971252270–275
100.
Ward HWC. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. BMJ19731584413–14
101.
BloomHJGDukesCEMitchleyBCVHormone-dependent tumours of the kidney I. The oestrogen-induced renal tumour op the Syrian hamster. Hormone treatment and possible relationship to carcinoma of the kidney in man. Br J Cancer1963174611–645
102.
CashRBroughAJCohenMNPSatohPSAminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab19672791239–1248
103.
JensenEVEstrogen receptors in hormone-dependent breast cancers. Cancer Res19753511 Pt. 23362–3364
CohenMHJohnsonJRLiNChenGPazdurRApproval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res200283665–669
DenmeadeSRIsaacsJTA history of prostate cancer treatment. Nat Rev Cancer200225389–396
108.
AndersonKMLiaoSSelective retention of dihydrotestosterone by prostatic nuclei. Nature19682195151277–279
109.
LiaoSHowellDKChangTMAction of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 α-dihydrotestosterone in rat ventral prostate. Endocrinology19749441205–1209
110.
VarenhorstEWallentinLCarlströmKThe effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol198216131–36
111.
WeberJReview: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist2007127864–872
112.
ChesonBDRituximab: clinical development and future directions. Expert Opin Biol Ther20022197–110
113.
Grillo-LópezAJWhiteCAVarnsCOverview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol1999265 Suppl 1466–73
Amiri-KordestaniLWedamSZhangLFirst FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res201420215359–5364
119.
HodiFSO'DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med20103638711–723
